Press releases
- Everest Medicines Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Etrasimod in Asia
- Nefecon Included in the Reimbursement Drug List of "Beijing Puhui Health Insurance Program" as a First-in-Disease Therapy for IgA Nephropathy
- Everest Medicines Launches Nefecon in China's Hainan Boao Pilot Zone as a First-in-Disease Therapy for IgA Nephropathy
- Everest Medicines Announces Strategic Partnership with Shanghai Pharma Subsidiary to Accelerate the Commercialization of XERAVA in Mainland China
- Everest Medicines Announces New Drug Application Acceptance by Singapore HSA for Nefecon for the Treatment of Primary IgA Nephropathy
- Everest Medicines Announces Financial Results for Full Year Ended December 31, 2022
- Everest Medicines Receives Full Upfront Payment from Gilead for Trodelvy-Related Transaction, Boosting Pro Forma Cash Reserves
- Everest Medicines Announces Signing of an MOU for Strategic Cooperation with Guangdong Academy of Medical Sciences in Renal Diseases
- Everest Medicines Announces Approval of Xerava in China for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients
- Everest Medicines to Announce Full-Year 2022 Financial Results on March 31, 2023
More ▼
Key statistics
As of last trade, Everest Medicines Ltd (6HN:MUN) traded at 1.38, 71.22% above the 52 week low of 0.806 set on Nov 01, 2022.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.38 |
---|---|
High | 1.38 |
Low | 1.38 |
Bid | 1.30 |
Offer | 1.39 |
Previous close | 1.41 |
Average volume | 0.00 |
---|---|
Shares outstanding | 315.55m |
Free float | 308.11m |
P/E (TTM) | -- |
Market cap | 3.70bn HKD |
EPS (TTM) | -0.9456 HKD |
Data delayed at least 15 minutes, as of May 29 2023 07:05 BST.
More ▼